₹239.80
−4.37%NSE close, 16 Nov 2026
−42.21%
AVIENCE BIOMEDICALS is a small cap company, listed on NSE SME under the symbol AVIENCE. At ₹239.80 a share, the market values the whole company at ₹132 crore. NSE SME is the exchange's platform for small and medium companies, which report their results every half year.
In FY26, it reported sales of ₹53 crore and a net profit of ₹9 crore, an operating margin of 28.5%.
The market values the company at 13.5 times its profit over the last twelve months and 2.13 times its book value; its return on equity is 15.8% and its borrowings are 0.44 times its equity.
Promoters hold 64.59% of the shares. Foreign institutions hold 0.03%, and domestic institutions, mutual funds among them, 3.48%.
Listed on NSE SME, the platform for small and medium companies: its shares trade in large lots and often thinly, so the price can move sharply on a few trades, and companies file results every half year.
₹ crore. Consolidated figures.
| Line | 6M to Mar 2026 | 6M to Sep 2026 |
|---|---|---|
| Sales | 25.7 | 31.1 |
| Expenses | 18.0 | 22.8 |
| Operating profit | 7.7 | 8.4 |
| Operating margin | 29.9% | 26.9% |
| Other income | 0.2 | 0.5 |
| Interest | 0.9 | 0.6 |
| Depreciation | 0.7 | 0.8 |
| Profit before tax |
Schedule of meet
The financial results for the period ended September 30, 2026.
Has informed regarding Submission of the Compliance Report on Corporate Governance for the Q 30 September, 2026 FY 2026-27
| 7.5 |
| Tax | 2.2 | 2.0 |
|---|
| Net profit | 4.2 | 5.5 |
|---|
| EPS (₹) | 10.45 | 10.10 |
|---|
₹ crore, financial years to March.
| Line | FY26 |
|---|---|
| Sales | 52.5 |
| Expenses | 37.6 |
| Operating profit | 14.9 |
| Operating margin | 28.5% |
| Other income | 0.3 |
| Interest | 1.5 |
| Depreciation | 1.2 |
| Profit before tax | 12.5 |
| Tax | 3.7 |
| Net profit | 8.8 |
| EPS (₹) | 21.71 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY26 | 6M to Sep 2026 |
|---|---|---|
| From operations | 5.9 | −5.7 |
| From investing | −13.3 | −18.4 |
| From financing | 5.4 | 22.2 |
| Spent on fixed assets | −13.5 | −13.8 |
| Free cash flow | −7.5 | −19.5 |
Margins, returns, debt, tax and cash.
| Line | FY26 |
|---|---|
| Net margin | 16.7% |
| Operating margin | 28.5% |
| Return on equity | 27.9% |
| Return on capital employed | 23.2% |
| Return on assets | 11.7% |
| Debt to equity | 0.92 |
| Interest coverage | 9.10 |
| Debt to assets | 0.39 |
| Current ratio | 1.46 |
| Quick ratio | 0.88 |
| Cash ratio | 0.00 |
| Asset turnover | 0.70 |
| Fixed asset turnover | 3.30 |
| Inventory turnover | 1.70 |
| Receivables turnover | 2.50 |
| Gross margin | 45.1% |
| Cash from operations to profit | 68.0% |
| Effective tax rate | 29.8% |
Outcome of Investor Conference
A copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results.
Change in Auditors of the company.
Proceedings of Annual General Meeting held on September 30, 2026
Schedule of meet
Intimation of AGM, Book Closure and cutoff date for evtoing
The Company has sent Letter to the Shareholder for AGM whose email id is not registered witht the Depository
Notice of Annual General Meeting to be held on September 30, 2026
Avience Biomedicals Limited has informed the Exchange regarding 'Intimation of Annual General Meeting
Outcome of Board Meeting held on September 07, 2026.
The financial results for the period ended March 31, 2026.